HOUSTON, Feb. 22, 2021 /PRNewswire/ — NuProbe, a genomics and molecular diagnostics company…
Rapid Development
Sensitive Mutation, Indel and CNV Detection
Low Input DNA
Gene selection and Coverage options
VarMap™: NGS
Features
Affordable
Only 1 million reads for liquid biopsy
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Sample Flexibility
Compatible with several sample types
Sample Data

VarMap NGS Panels preferentially amplify variant molecules, resulting in a reduction of required sequencing reads by 60-fold compared to deep sequencing approaches.
Products
VarMap™ Pan-Cancer NGS Panel
Detects over 6300 COSMIC mutations in over 60 genes
CNV+: NGS
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Quantitative
>95% VAF quantitation accuracy
Quick Turnaround Time
6-hour DNA-to-Library workflow
Sample Flexibility
Compatible with several sample types
Sample Data

CNV+ panels use QASeq technology, which is more sensitive than ddPCR. The panels detect deletions and mutations, that can not be done with IHC. QASeq technology allows analyzing thousands of loci, while ddPCR analyzes 1 locus.
Products
CNV+ Breast Cancer NGS Panel
Detects 84 mutation hotspots in 14 genes and detect ERBB2 Copy Number Variations (CNVs) in a single reaction
VarTrace™: qPCR, Sanger
Features
Ultrasensitive
Limit of detection down to 0.1% VAF
Comprehensive
Detects up to 500 COSMIC mutations
Quantitative
Accurate quantitation
Sample Flexibility
Compatible with several sample types
Sample Data
NuProbe’s BDA technology enriches the variant allele frequency (VAF) of mutations by over 200-fold, improving Sanger’s limit of detection of 20% VAF to 0.1% VAF.
Products
VarTrace™ AML Panel
Detects 254 AML hotspot mutations in FLT3, DNMT3A, IDH1, IDH2, KIT, NPM1 genes
VarTrace™ EGFR Assay
Detects 400 mutations in exons 18, 19, 20, and 21 in FFPE and plasma samples
VarTrace™ BRAF Assay
Detects mutations in codons 596–601 in FFPE and plasma samples
Customized qPCR/Sanger Assays and Services
Features
Customizable
Automatically design custom BDA assays
Rapid Turnaround
2-3 days
Ultrasensitive
Limit of detection down to 0.1% VAF
Sample Data

NGSure’s proprietary algorithm designs custom BDA assays with a limit of detection of 0.1% VAF, significantly expanding the range of mutations detected by NGS.
News & Press Releases
HOUSTON and SHANGHAI, Jan. 11, 2021 /PRNewswire/ — NuProbe, a genomics and molecular diagnostics company…
HOUSTON, Nov. 16, 2020 /PRNewswire/ — NuProbe, an innovator of genomics…
HOUSTON, June 22, 2020 /PRNewswire/ — NuProbe and Weigao Group…
HOUSTON, April 22, 2020 /PRNewswire/ — NuProbe, a molecular diagnostic…